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Deferiprone or deferasirox for cardiac siderosis inβ thalassemia major (reply)
We thank KM Musallam and Ali T Taher1 to have given
us the opportunity to comment on our study more exten-
sively. Firstly, to date, the goal of the physician responsi-
ble for the management of thalassemia is to tailor the
chelation therapy for each patient according to the iron
status in crucial organs like the heart and the specific effi-
cacy of the different chelators. Thus, formal comparison
in this phase are recommended. Our study is retrospec-
tive and this issue is clearly stressed in the paper. 
Considering all three treatment groups together (des-
ferrioxamine, deferiprone and deferasirox) we found a
significant difference in the active treatment duration
(P=0.001). At multiple comparisons, only desferrioxam-
ine had been started significantly earlier than deferiprone
and deferasirox but the time of active treatment was
more comparable between deferiprone and deferasirox
(P=0.100). Moreover, the group with longer active treat-
ment was not the most effective. This supports data sug-
gesting that not only the time of treatment but also
intrinsic proprieties of the drugs explain their efficacy. We
categorized patients who received the drugs for similar
intervals of time and compared them in a secondary
analysis. Because the duration of deferasirox therapy
ranged from one to five years, we restricted the analysis
to this duration of active chelation therapy. There were
30 patients in the deferiprone group, 24 patients in the
deferasirox group and only 9 patients in the desferriox-
amine group. The duration of the treatment was more
homogeneous (P=0.442) in these treatment subgroups
than when the overall groups were compared. Results of
the comparison between the deferiprone and the
deferasirox subgroups are shown in Table 1 and con-
firmed results observed when the overall groups were
considered. Confidence intervals are also reported.
We tried to reduce the bias due to the retrospective
analysis by reporting data to support the homogeneity of
the three groups analyzed. The deferiprone and
deferasirox groups showed comparable basal mean
serum ferritin levels; therefore, we cannot attribute the
results concerning the deferiprone group to a lower base-
line iron burden. We agree with Musallam and Taher1
regarding the complex relationship between cardiac iron
and total body iron balance. In a cross sectional analysis
in patients with a long history of chelation treatments,
cardiac T2* does not correlate with serum ferritin con-
centration. Serum ferritin levels cannot be used, there-
fore, to predict cardiac iron.2 Due to the comparable base-
line ferritin levels, the lower heart T2* values found in
the deferasirox group seem not to be related to a higher
initial total iron load. Moreover, in all three groups at
comparable levels of excellent/good compliance there
were no significant differences in the basal mean serum
ferritin levels in the 12 months before starting the active
treatment and the mean serum ferritin levels in the last
year of the active treatment. There was no significant
increase in the mean serum ferritin levels in the
deferasirox group as stated by the authors. However, we
do not intend to draw attention to this. In fact, basal
mean serum ferritin levels in the 12 months before start-
ing the active treatment could also refer to many years
before (see the active treatment duration) and the mean
serum ferritin levels in the last year of the active treat-
ment do not reflect the entire follow-up time between
the two magnetic resonance imaging (MRI) scans (15-21
months).
Knowledge of the iron intake in our study population
would have improved the interpretation of the data but
unfortunately we did not have the information available
in the data base. Comparable pre-transfusion hemoglo-
bin level, percentages of splenectomized patients, and
standardized and homogeneous transfusion regimens in
our study population do not mean comparable iron
intakes, although an imbalance in one group is unlikely.
Moreover, multicenter randomized clinical trials, in
which a significant number of the patients in this obser-
vational study had been previously enrolled, suggested
blood transfusion requirement was comparable among
the different chelation treated groups.3-5
However, we perfectly agree with Musallam and Taher
that large prospective studies comparing the efficacy of
deferiprone and deferasirox in removing and preventing
cardiac siderosis are needed. All retrospective data should
be developed first and only after that should prospective
data be collected. We have recently presented our
prospective data to the 2010 ASH Annual Meeting in
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Table 1. Comparison between the deferiprone and the deferasirox subgroups.
Deferiprone group Deferasirox group P Difference
(N=30) (N=24)
mean±SD 95% CI mean±SD 95% CI mean 95% CI
Age (years) 31±8 26±7 0.001
Age at start of chelation (years) 8±10 5±5 ns
Active treatment duration 2.7±1.2 2.3-3.2 2.2±1.4 1.7-2.8 ns 0.5 -0.2-1.2
Baseline mean serum ferritin (ng/mL) 1755±2277 872-2638 2491±2072 1460-3521 ns -736 -2075-604
Global heart T2* (ms) 34.1±12.3 29.5-38.8 21.2±12.1 16.1-26.3 0.001 12.9 6.2-19.7
Liver T2* (ms) 6.8±6.9 4.2-9.4 5.2±5.0 3.1-7.3 ns 1.6 -1.7-5.0
Left ventricular EF (%) 64.0±6.3 61.6-66.4 59.1±7.1 55.9-62.2 0.012 4.9 1.1-8.7
Mean serum ferritin (ng/mL) 1669±1849 952-2386 2361±2010 1446-3276 ns -692 -1806-423
Pts with global heart T2*<20 ms (%) 16.7 62.5 0.001
ns: not significant; EF: ejection fraction.
which the changes in cardiac T2* expressed as mean dif-
ference were measured in a large cohort of thalassemia
patients who had received one chelator alone between
the baseline magnetic resonance imaging and MRI fol-
low-up study at 18 ± 3 months.6 These preliminary data
confirm deferiprone monotherapy to be more effective
than deferasirox in improving myocardial siderosis and a
comparable efficacy between deferasirox and desferriox-
amine.
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